Key facts
- This page summarizes Andreas Busch's Form 4 filing for Cyclerion Therapeutics, Inc. (CYCN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Jan 2022, 10:48.
Andreas Busch - 20 Jan 2022 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- CYCN
- Reported as of
- 20 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2022, 10:48:43 UTC
- Prior SEC filing
- 10 Dec 2021
- Next SEC filing
- 21 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gary J. Simon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andreas Busch filed Form 4 for Cyclerion Therapeutics, Inc. (CYCN) on 24 Jan 2022.
Change
- Previous filing in this sequence was filed on 10 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYCN
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +135,000
- Change %
- Price
- $0.000000
- Shares after
- 135,000
- Date
- 20 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 135,000
- Exercise price
- $1.21
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.